-
Casirivimab/imdevimab, sold
under the
brand name REGEN‑COV
among others, is a
combination medicine used for the
treatment and
prevention of COVID‑19....
- 2020, the
monoclonal antibody therapies bamlanivimab/etesevimab and
casirivimab/imdevimab were
given emergency use
authorizations by the US Food and...
- the
public domain. "
Casirivimab injection, solution,
concentrate Imdevimab injection, solution,
concentrate REGEN-COV –
casirivimab and
imdevimab kit"...
- 28
October 2020. "
Casirivimab injection, solution,
concentrate Imdevimab injection, solution,
concentrate REGEN-COV-
casirivimab and
imdevimab kit"....
- Bebtelovimab§
Casirivimab† (+imdevimab) Cilgavimab† (+tixagevimab)† Diridavumab§ Etesevimab† Exbivirumab§ Foravirumab§ Imdevimab† (+
casirivimab) Libivirumab§...
-
against use of
plasma in COVID-19 in
December 2021.
Monoclonal antibodies (
casirivimab/imdevimab) were
developed for the
treatment of COVID-19. On June 7, 2021...
- 12
November 2021. "****an
becomes first country to
approve Ronapreve (
casirivimab and imdevimab) for the
treatment of mild to
moderate COVID-19". Roche...
-
antibody treatments – bamlanivimab/etesevimab (administered together) and
casirivimab/imdevimab – to
limit their use to only when the
recipients are likely...
- be
effective against Delta on its own. At high
enough concentrations,
casirivimab,
etesevimab and
imdevimab appear to
still be effective. A
preprint study...
- 2021, the
monoclonal antibody therapies bamlanivimab/etesevimab and
casirivimab/imdevimab were
found to
reduce the
number of hospitalizations, emergency...
